Our findings indicate that CILP2 contributes to hepatic lipid accumulation and inflammation via the IRE1α/XBP1 pathway and may represent a potential therapeutic target for MASLD intervention. This evidence concerns the gene XBP1 and metabolic dysfunction-associated steatotic liver disease.